Salivary gland disorder

This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…

This phase 3 study tests whether ianalumab, a biologic drug, can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 506 adults with a recent diagnosis (within 7.5 years) and positive anti-Ro/SSA antibodies are randomly assigned to receive ianalum…

This phase 2 trial is testing two hormone-blocking drugs—darolutamide and leuprolide acetate—in 21 patients with advanced salivary gland cancer that has spread or returned. The cancer must have a protein called androgen receptor. The goal is to see if the combination can shrink t…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…

This study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary…

This study tests whether a combination of two hormone-blocking drugs (apalutamide and a GnRH agonist) can shrink or slow the growth of advanced salivary gland cancer that has a specific protein called the androgen receptor. About 31 adults with locally advanced or spread cancer t…

This phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…

This study tests if a new 2mL auto-injector or pre-filled syringe delivers the same amount of the drug ianalumab into the body as the current 1mL syringe. About 155 adults with rheumatoid arthritis, Sjögren's disease, or lupus will receive the drug both ways to compare how much g…

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This study looks at whether adding chemotherapy (cisplatin) to standard radiation therapy after surgery helps people with high-risk salivary gland tumors live longer without the cancer returning. About 252 adults whose tumors were removed took part. The goal is to see if the comb…

This phase 3 study tests whether the drug ianalumab can reduce disease activity in people with active Sjogren's syndrome. About 275 adults with the condition will receive either ianalumab or a placebo shot under the skin. The main goal is to see if the drug improves symptoms and …

This phase 2 trial tests whether amivantamab can shrink tumors or slow disease in 21 people with recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Participants receive weekly or biweekly infusions of the drug. The main goal is to see how many patient…

This phase 3 study tests the long-term safety of ianalumab in 612 people with Sjögren's syndrome who already completed a year of treatment in earlier trials. Participants receive ianalumab or placebo injections for up to several more years. The goal is to see if the drug remains …

This phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…

This study is testing whether a precise form of radiation called proton therapy can control head and neck cancer after surgery as well as standard X-ray radiation, but with fewer side effects. About 174 adults with newly diagnosed head and neck cancer will receive either proton t…

This study tests whether giving targeted drugs based on the genetic makeup of a person's advanced salivary gland cancer can shrink tumors or stop them from growing. About 88 adults with cancer that has spread or come back are enrolled. Researchers are checking how well these trea…

This phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…

This Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…

This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug docetaxel can shrink or control advanced thyroid and salivary gland cancers that are not responding to standard treatments. About 46 participants will receiv…

This study tests a new drug called APG-115, alone or with chemotherapy, in people with a certain type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults with…

This study tests enzalutamide, a drug already approved for other cancers, in 46 people with a specific type of salivary gland cancer that has androgen receptors. The goal is to see if the drug can shrink tumors by at least 30% in 1 out of 5 patients. Researchers will also track h…

This early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This Phase 3 trial tests dazodalibep, a drug given by IV, in 651 people with moderate-to-severe Sjögren's syndrome. The goal is to see if it reduces disease activity and improves symptoms like dryness and fatigue. Participants receive either the drug or a placebo, and researchers…

This early-phase trial is testing the safety of tofacitinib (Xeljanz), a drug already used for rheumatoid arthritis, in 23 adults with mild-to-moderate Sjogren's syndrome. Participants take the drug or a placebo daily for 168 days. The goal is to see if the drug is safe and toler…

This study tests whether two drugs, lenvatinib and pembrolizumab, can shrink or slow the growth of advanced salivary gland cancers, including adenoid cystic carcinoma, that have come back or spread. About 64 participants will receive the combination therapy. The goal is to see ho…

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This study compares using cyclosporine eye drops alone versus combining them with absorbable punctal plugs for dry eye caused by Sjögren's syndrome. Thirty participants will receive the drops in both eyes and a plug in one eye to see if the combination improves symptoms better. T…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study tests whether using home sensors to monitor dehydration risk can reduce hospitalizations and emergency room visits in head and neck cancer patients. About 427 participants will either use the CYCORE sensor system plus standard care, or standard care alone. The goal is …

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…

This study compares a new, minimally invasive keyhole surgery (endoscopic parotidectomy) to the standard open surgery for removing benign (non-cancerous) tumors from the parotid gland, a major salivary gland. The goal is to see if the keyhole approach is as safe and effective, wi…

This study tests an experimental drug called dazodalibep in 434 adults with moderate-to-severe Sjögren's syndrome, an autoimmune disease causing dryness, fatigue, and pain. Participants receive either the drug or a placebo to see if it improves symptoms like dry eyes and mouth. T…

This study compares proton beam radiation to standard photon radiation (IMRT) for people with head and neck cancer. The goal is to see if proton therapy causes fewer side effects, like painful mouth sores, by exposing less healthy tissue to radiation. About 108 adults with certai…

This study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …

This study looks at immune system markers in the saliva and blood of 80 people with primary Sjögren's syndrome, a chronic disease causing dry eyes and mouth. Researchers will check for antibodies that may block a key enzyme and see how gum disease affects symptoms. The goal is to…

This study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…

This study looks at whether changes in gut bacteria can affect Sjögren's syndrome, an autoimmune disease causing dry eyes, dry mouth, and fatigue. Researchers will measure blood markers of gut leakage in 50 adults with Sjögren's to see if these markers change when disease activit…

This study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…